Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A (RT) | Experimental | Period 1: Reference Drug (AD-2284), Period 2: Test Drug (AD-228B) |
|
| Sequence B (TR) | Experimental | Period 1: Test Drug (AD-228B), Period 2: Reference Drug (AD-2284) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-228B | Drug | AD-228B, 1Tab., Per Oral |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum concentration of drug in plasma (Cmax) | Cmax of AD-228B | pre-dose (0hour) to 72hours |
| Area under the plasma concentration-time curve during dosing interval (AUCt) | AUCt of AD-228B | pre-dose (0hour) to 72hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| JeongEun Park | Contact | +82-31-891-6989 | parkje@addpharma.co.kr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| H Plus Yangji Hospital | Recruiting | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AD-2284 |
| Drug |
AD-2284, 1Tab., Per Oral |
|